Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients
Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.
EP: 1.Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer
EP: 2.Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial
EP: 3.Outcomes from NATALEE and MonarchE
EP: 4.Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment
EP: 5.Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib
Now Viewing
EP: 6.Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients
EP: 7.Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema
EP: 8.Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib
EP: 9.Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors
EP: 10.How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor
EP: 11.Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors
EP: 12.Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies
EP: 13.ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer
Video content above is prompted by the following question(s):
- In the monarchE and NATALEE trials, the endocrine therapy allowed was different. How did the type of endocrine therapy used impact toxicities seen, and how has that translated to your practice when selecting endocrine therapies?
Related Videos
Related Content
